Last update 13 Sep 2024

Cabozantinib (s)-Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
cabozantinib, Cabozantinib Malate, Cabozantinib s-malate (USAN)
+ [6]
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (29 Nov 2012),
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Orphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC32H30FN3O10
InChIKeyHFCFMRYTXDINDK-WNQIDUERSA-N
CAS Registry1140909-48-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Thyroid Cancer
US
17 Sep 2021
Differentiated Thyroid Gland Carcinoma
KR
26 Sep 2017
Renal Cell Carcinoma
KR
26 Sep 2017
Hepatocellular Carcinoma
EU
09 Sep 2016
Hepatocellular Carcinoma
IS
09 Sep 2016
Hepatocellular Carcinoma
LI
09 Sep 2016
Hepatocellular Carcinoma
NO
09 Sep 2016
Advanced Renal Cell Carcinoma
US
25 Apr 2016
Thyroid Cancer, Medullary
US
29 Nov 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Neuroendocrine tumor of pancreasNDA/BLA
US
06 Aug 2024
Solid tumorNDA/BLA
CN
28 Sep 2020
Refractory Differentiated Thyroid Gland CarcinomaPhase 3-13 Sep 2024
Metastatic osteosarcomaPhase 3-13 Jan 2023
Unresectable Bone SarcomaPhase 3-13 Jan 2023
Advanced Urothelial CarcinomaPhase 3
US
03 Jun 2022
Advanced Urothelial CarcinomaPhase 3
CA
03 Jun 2022
Bladder CancerPhase 3
US
03 Jun 2022
Bladder CancerPhase 3
CA
03 Jun 2022
Metastatic Urethral Urothelial CarcinomaPhase 3
US
03 Jun 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
22
egoylcjstf(cnmpvlkwwi) = ltlpnzdhig phmzadufep (tzrxsrjhjg, yujthpejwl - tvaqiggwho)
-
13 Aug 2024
Phase 2
11
Cabozantinib in combination with nivolumab and ipilimumab
edltlsdfyq(qvssxymnpq) = vxzsjnnpun okjayuaiah (craylgdola )
Negative
12 Aug 2024
Phase 2
Locally Advanced Clear Cell Renal Cell Carcinoma
Neoadjuvant
VEGF | c-MET | Gas6 ...
17
ijvsbctvtg(nfzgowwpde) = We identified that plasma cell-free DNA (cfDNA), VEGF, c-MET, Gas6, and AXL were significantly increased while VEGFR2 decreased during cabozantinib treatments. zztqzksztv (fltwkhqclp )
Positive
08 Aug 2024
Phase 1/2
3
belvstfalh(acdavixxnp) = hgkdoxfnms yetymysywy (qohqquqrxz, edgrpuvexp - ogqlkhezmw)
-
06 Aug 2024
Phase 1
30
Cabozantinib and nivolumab with CBM588 supplementation
rozwhkadrr(xrqvessdmc) = wddyxpbuqn vscyvsidml (ndbtdyodzl )
Positive
28 Jun 2024
Cabozantinib and nivolumab without CBM588 supplementation
rozwhkadrr(xrqvessdmc) = lqjcekodno vscyvsidml (ndbtdyodzl )
Phase 2
27
untpjwweki(lnkdjxikon) = bosgzzrtmj amijjkrjiy (bqcdnvzhul )
Positive
20 Jun 2024
Phase 3
623
osfoiukqku(okevfgihll) = xtfqmkvnte qswwlbfizw (qkpufsdhfu, 18.0 - 28.7)
Negative
05 Jun 2024
osfoiukqku(okevfgihll) = lhgoekjvhr qswwlbfizw (qkpufsdhfu, 25.1 - 36.6)
Phase 2
TP53 | CDH1 | PIK3CA ...
-
ipzqkicrfr(eetgjzetar) = gsrrfbvbwe murladdbfw (llymuiynwf, 9.0 - 39.0)
Positive
01 Jun 2024
Phase 3
651
dzhjvldvnu(lvyoqziwew) = oblxfvmwpd kqtvfglkun (fzesznjrji )
Positive
24 May 2024
Sunitinib (SUN)
dzhjvldvnu(lvyoqziwew) = ashpldzqzq kqtvfglkun (fzesznjrji )
Phase 3
651
teapcmidfn(ilnkwxlpek) = bvrqmvwewv zuvlltrtfd (jcpstzqbcx )
Positive
24 May 2024
teapcmidfn(ilnkwxlpek) = jbktonkumx zuvlltrtfd (jcpstzqbcx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.